BRIEF

on VALBIOTIS (EPA:ALVAL)

VALBIOTIS launches Valbiotis®PRO for the prevention of metabolic diseases

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

Valbiotis is preparing to market Valbiotis®PRO Metabolic Health (Totum•63) in France, between February and March 2025. This dietary supplement targets the prevention of metabolic diseases, particularly type 2 diabetes. With 4 million diabetics and 2 to 3 million prediabetics in France, Valbiotis is targeting a major public health issue.

The product is based on the substance Totum•63, 100% plant-based and clinically validated. This innovation has been tested on 720 participants and benefits from 17 communications and 7 international publications. It has shown its effectiveness in reducing fasting blood sugar.

In line with the success of Valbiotis®PRO Cholesterol, distribution will be via pharmacies and an online channel. The products will be available with a recommended price starting at €22.95. The launch will involve a dedicated sales force to ensure promotion.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news